Akademisyen profili · PROFESÖR
ABDULLAH MÜNCİ YAĞCI
- TIP FAKÜLTESİ
- DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Scopus (SJR)
Q1
30
Q2
28
Q3
16
Q4
7
WoS (JCR)
Q1
10
Q2
13
Q3
28
Q4
31
TR Index
13
makale
Makaleler
- 2025 Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry
- 2025 COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study
- 2025 Day + 100 bone marrow megakaryocyte count predicts transplant outcome in patients with high-risk myelodysplastic syndrome and acute leukemia
- 2025 Radiofrequency Induced Time‐Dependent Alterations in Gene Expression and Apoptosis in Glioblastoma Cell Line
- 2025 Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial
- 2025 Frequency of NPM1 Mutation and Its Impact on Prognosis in Cytogenetically Normal AML Patients: Hyperleukocytosis Remains an Unfavorable Prognostic Marker Among NPM1 Positive Patients
- 2024 Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
- 2024 Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care
- 2024 C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
- 2023 Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
- 2023 Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
- 2023 Is flow cytometry useful in determining central nervous system involvement in patients with hematological malignancy? Analysis with a prospective cohort
- 2023 Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
- 2023 Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
- 2023 Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
- 2022 Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis
- 2022 Analysis of bone marrow samples by the SYSMEX‐XN20 hematology analyzer
- 2022 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
- 2022 Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis
- 2022 Occurrence of familial Mediterranean fever in haemophilia patients